Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension
NCT03282266 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128
Last updated 2025-10-03
Summary
The objective of this randomized control trial is to gain clinical insight on the use of pulmonary artery denervation (PADN) for the treatment of pulmonary arterial hypertension (PAH). The primary objective is to assess effectiveness and safety of PADN for the treatment of PAH.
Conditions
Interventions
- PROCEDURE
-
PADN
PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
- PROCEDURE
-
Sham operation
The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
Sponsors & Collaborators
-
Pulnovo Medical (Wuxi) Co., Ltd.
collaborator INDUSTRY -
Guangdong Provincial People's Hospital
collaborator OTHER -
The First Affiliated Hospital of Zhengzhou University
collaborator OTHER -
Tianjin Medical University General Hospital
collaborator OTHER -
First Affiliated Hospital Xi'an Jiaotong University
collaborator OTHER -
Beijing Anzhen Hospital
collaborator OTHER -
Shenyang Northern Hospital
collaborator OTHER -
The Second Affiliated Hospital of Chongqing Medical University
collaborator OTHER -
Tongji Hospital
collaborator OTHER -
Nanjing First Hospital, Nanjing Medical University
lead OTHER
Principal Investigators
-
Hang Zhang, MD · Nanjing First Hospital, Nanjing Medical University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-18
- Primary Completion
- 2021-06-22
- Completion
- 2021-12-22
Countries
- China
Study Locations
More Related Trials
-
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467 ·Status: RECRUITING
-
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
NCT05372263 ·Status: RECRUITING
-
Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension
NCT05437224 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension
NCT04055415 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
NCT06554301 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
NCT05699486 ·Status: UNKNOWN ·Phase: PHASE2
-
An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
NCT02882126 ·Status: WITHDRAWN ·Phase: PHASE4
-
A First-in-Human Study to Assess the Safety and Tolerability of PDNO
NCT04891354 ·Status: COMPLETED ·Phase: PHASE1
-
rhBNP in Type 3 Pulmonary Hypertension
NCT05716984 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy
NCT03145298 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Triple-Combination Therapy in Severe PAH-CHD
NCT06196801 ·Status: ACTIVE_NOT_RECRUITING
-
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
NCT06605326 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Sequential to Initial Combination Therapy in PAH
NCT06968962 ·Status: RECRUITING ·Phase: NA
-
Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
NCT01066845 ·Status: COMPLETED
-
The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery
NCT05727618 ·Status: SUSPENDED ·Phase: NA
-
Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)
NCT04968210 ·Status: COMPLETED
-
Combination Therapy in Pulmonary Arterial Hypertension
NCT00433329 ·Status: COMPLETED ·Phase: PHASE4
-
Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
NCT01548950 ·Status: COMPLETED ·Phase: NA
-
Patient Reported Outcomes in Pulmonary Arterial Hypertension
NCT01792622 ·Status: WITHDRAWN
-
Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension
NCT06980584 ·Status: RECRUITING ·Phase: NA
-
Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH
NCT03841344 ·Status: UNKNOWN ·Phase: NA
-
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
NCT01712997 ·Status: UNKNOWN ·Phase: PHASE3
-
Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
NCT02304198 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
NCT00423202 ·Status: COMPLETED ·Phase: PHASE3
-
Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease
NCT02742909 ·Status: COMPLETED ·Phase: PHASE4